
==== Front
Adv TherAdv TherAdvances in Therapy0741-238X1865-8652Springer Healthcare Cheshire 31502216108210.1007/s12325-019-01082-6CorrectionCorrection to: Cardiovascular Risks, Bleeding Risks, and Clinical Events from 3 Phase III Trials of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis Glassberg Marilyn K. MGlassbe@med.miami.edu 1Nathan Steven D. 2Lin Chin-Yu 3Morgenthien Elizabeth A. 3Stauffer John L. 3Chou Willis 4Noble Paul W. 51 grid.418456.a0000 0004 0414 313XUniversity of Miami Health System, Miami, FL USA 2 grid.417781.c0000 0000 9825 3727Inova Fairfax Hospital, Falls Church, VA USA 3 grid.418158.10000 0004 0534 4718Genentech, Inc., South San Francisco, CA USA 4 grid.421404.70000 0004 0409 3312FibroGen, San Francisco, CA USA 5 grid.50956.3f0000 0001 2152 9905Cedars-Sinai Medical Center, Los Angeles, CA USA 9 9 2019 9 9 2019 2019 36 10 2927 2929 © The Author(s) 2019Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.issue-copyright-statement© Springer Healthcare Ltd., part of Springer Nature 2019
==== Body
Correction to: Adv Ther 10.1007/s12325-019-01052-y
In the original publication the colors of Fig. 2 have been switched. The corrected Fig. 2 is given belowFig. 2 Time to first major adverse cardiac event–plus (a) and time to first bleeding event (b)

